2. Search Result
Search Result
Results for "

2AG

" in MedChemExpress (MCE) Product Catalog:

25

Inhibitors & Agonists

1

Fluorescent Dye

2

Natural
Products

4

Recombinant Proteins

2

Isotope-Labeled Compounds

5

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15249
    JZL 184
    Maximum Cited Publications
    8 Publications Verification

    		 MAGL Neurological Disease
    JZL 184 is a potent, selective and irreversible MAGL inhibitor that blocks 2-Arachidonoylglycerol (2-AG) hydrolysis in brain membranes (IC50 of 8 nM). JZL 184 displays >300-fold selectivity for MAGL over FAAH [2].
    JZL 184
  • HY-117474
    MJN110
    5 Publications Verification

    		 MAGL Neurological Disease
    MJN110 is an orally active and selective monoacylglycerol lipase (MAGL) inhibitor with IC50s of 9.1 nM and 2.1 nM for hMAGL and 2-arachidonoylglycerol (2-AG), respectively . MJN110 produces opioid-sparing effects and displays strong antihyperalgesic activity [2].
    MJN110
  • HY-117771
    DO34
    5 Publications Verification

    		 DAGL Neurological Disease Metabolic Disease
    DO34 is a selective DAGL inhibitor, with an IC50 of 6 nM for DAGLα conversion of SAG to 2-AG. DO34 blocks de novo 2-AG synthesis, and suppresses tonic CB1 receptor activation. DO34 blocks depolarization-induced suppression of excitation and inhibition in the cerebellum and hippocampus. DO34 regulates feeding behavior and locomotor activity in mice. DO34 abolishes AM251-mediated enhancement of parallel fiber-evoked excitatory postsynaptic currents in cerebellar slices from MAGL global knockout mice. DO34 can be used for the research of energy balance disorder and neuroinflammation [2] .
    DO34
  • HY-133130
    JNJ-42226314
    1 Publications Verification

    		 MAGL Neurological Disease
    JNJ-42226314, a chemical probe, is a competitive, highly selective and reversible non-covalent monoacylglycerol lipase (MAGL) inhibitor. JNJ-42226314 demonstrates dose-dependent enhancement of the major endocannabinoid 2-arachidonoylglycerol (2-AG) as well as efficacy in models of neuropathic and inflammatory pain .
    JNJ-42226314
  • HY-132310
    MAGL-IN-4

    		MAGL Neurological Disease
    MAGL-IN-4 is an orally active, selective and reversible monoacylglycerol lipase (MAGL) inhibitor with an IC50 of 6.2 nM. MAGL-IN-4 can penetrate the blood-brain barrier (BBB). MAGL-IN-4 enhances endocannabinoid signaling mostly by the increase in the level of 2-AG via selective MAGL inhibition in the brain .
    MAGL-IN-4
  • HY-120851
    O-7460

    		Cannabinoid Receptor DAGL Metabolic Disease
    O-7460 is a potent and selective DAGLα inhibitor, with an IC50 of 0.69 μM. O-7460 shows selectivity over onoacylglycerol lipase (MAGL), human CB1 and CB2 cannabinoid receptors. O-7460 can decrease HFD-caused an up-regulation of 2-AG levels .
    O-7460
  • HY-118653
    SAR629

    		MAGL Metabolic Disease
    SAR629 is a potent monoglyceride lipase (MGL) covalent inhibitor. SAR629 also inhibits 2-Arachidonoylglycerol (2-AG) degradation [2].
    SAR629
  • HY-117771A
    DO34 analog

    		DAGL Neurological Disease Metabolic Disease
    DO34 analog is a structural analog of DO34 (HY-117771). DO34 is a selective DAGL inhibitor, with an IC50 of 6 nM for DAGLα conversion of SAG to 2-AG. DO34 can be used for the research of energy balance disorder and neuroinflammation [2] .
    DO34 analog
  • HY-15249R
    JZL 184 (Standard)

    		MAGL Reference Standards Neurological Disease
    JZL 184 (Standard) is the analytical standard of JZL 184. This product is intended for research and analytical applications. JZL 184 is a potent, selective and irreversible MAGL inhibitor that blocks 2-Arachidonoylglycerol (2-AG) hydrolysis in brain membranes (IC50 of 8 nM). JZL 184 displays >300-fold selectivity for MAGL over FAAH [2].
    JZL 184 (Standard)
  • HY-W013788
    2-Palmitoylglycerol

    2-Palm-Gl

    		 Cannabinoid Receptor Neurological Disease
    2-Palmitoylglycerol (2-Palm-Gl), an congener of 2-arachidonoylglycerol (2-AG), is a modest cannabinoid receptor CB1 agonist. 2-Palmitoylglycerol also may be an endogenous ligand for GPR119 .
    2-Palmitoylglycerol
  • HY-117718
    AG957

    Tyrphostin AG957; NSC 654705

    		 Bcr-Abl Cancer
    AG957 (Tyrphostin AG957;NSC 654705) is a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity [2]. AG957 is a bcr/abl kinase inhibitor with an IC50 of 2.9 μM for p210 bcr/abl autokinase activity .
    AG957
  • HY-162315
    MAGL-IN-16

    		MAGL Neurological Disease
    MAGL-IN-16 (compound 27) is an oral active, selective and reversible MAGL inhibitor with the IC50 value of 10.3 nM. MAGL-IN-16 can increase the level of 2-AG and shows antidepressant effect in mouse depressed model caused by chronic restraint stress .
    MAGL-IN-16
  • HY-158362A
    Monoglyceride lipase, Bacillus sp.

    		Endogenous Metabolite Neurological Disease Metabolic Disease Inflammation/Immunology
    Monoglyceride lipase, Bacillus sp., is a key enzyme involved in lipid metabolism. It catalyzes the hydrolysis of monoglycerides (particularly 2-AG, or 2-arachidonoylglycerol) into glycerol and free fatty acids. By regulating the levels of 2-AG, Monoglyceride lipase, Bacillus sp., can influence neural signaling, pain perception, inflammatory responses, and metabolic processes .
    Monoglyceride lipase, Bacillus sp.
  • HY-173296
    MAGL-IN-222

    		Lipase Cancer
    MAGL-IN-222 (Compound ZQ-7) is a covalent inhibitor targeting monoacylglycerol lipase (MAGL) with an IC50 of 42.31 μM. MAGL-IN-222 can reduce the breakdown of 2-arachidonoylglycerol (2-AG) and increase the intracellular 2-AG level, thereby inhibiting the proliferation and migration of MDA-MB-231 breast cancer cells. MAGL-IN-222 can be used in the research of breast cancer and other related diseases .
    MAGL-IN-222
  • HY-120560
    OMDM169

    		MAGL Neurological Disease
    OMDM169 is a potent and selective monoacylglycerol lipase (MAGL) inhibitor with activity to increase 2-AG levels. OMDM169 exerts analgesic activity through indirect activation of cannabinoid receptors. The effective concentration of OMDM169 is 0.13 μM .
    OMDM169
  • HY-W013788R
    2-Palmitoylglycerol (Standard)

    2-Palm-Gl (Standard)

    		 Reference Standards Cannabinoid Receptor Neurological Disease
    2-Palmitoylglycerol (Standard) is the analytical standard of 2-Palmitoylglycerol. This product is intended for research and analytical applications. 2-Palmitoylglycerol (2-Palm-Gl), an congener of 2-arachidonoylglycerol (2-AG), is a modest cannabinoid receptor CB1 agonist. 2-Palmitoylglycerol also may be an endogenous ligand for GPR119 .
    2-Palmitoylglycerol (Standard)
  • HY-131995
    O-Arachidonoyl glycidol

    		Cannabinoid Receptor Metabolic Disease
    O-Arachidonoyl glycidol (compound 1) is a 2-arachidonoylglycerol (2-AG) analog. O-Arachidonoyl glycidol inhibits cytosolic 2-oleoylglycerol (2-OG) hydrolysis with an IC50 value of 4.5 µM. O-Arachidonoyl glycidol blocks 2-OG hydrolysis in membrane fractions and anandamide hydrolysis with IC50s of 19, 12 µM, respectively .
    O-Arachidonoyl glycidol
  • HY-116143
    MAGL-IN-12

    		MAGL Metabolic Disease
    SAR127303 is an orally active, selective, competitive monoacylglycerol lipase (MAGL) covalent inhibitor with IC50s of 3.8 nM and 29 nM for mouse and human MAGL, respectively. SAR127303 potently elevates hippocampal levels of 2-AG in mice. SAR127303 decreased long term potentiation (LTP) of CA1 synaptic transmission and acetylcholine release in the hippocampus. SAR127303 produces antinociceptive effects in assays of inflammatory and visceral pain. SAR127303 slows down epileptogenesis .
    MAGL-IN-12
  • HY-W742940
    O-Arachidonoyl glycidol-d5

    		Isotope-Labeled Compounds Cannabinoid Receptor Metabolic Disease
    O-Arachidonoyl glycidol-d5 is the deuterium labeled O-Arachidonoyl glycidol (HY-131995). O-Arachidonoyl glycidol (compound 1) is a 2-arachidonoylglycerol (2-AG) analog. O-Arachidonoyl glycidol inhibits cytosolic 2-oleoylglycerol (2-OG) hydrolysis with an IC50 value of 4.5 μM. O-Arachidonoyl glycidol blocks 2-OG hydrolysis in membrane fractions and anandamide hydrolysis with IC50s of 19, 12 μM, respectively .
    O-Arachidonoyl glycidol-d5
  • HY-165060
    (±)2-(14,15-Epoxyeicosatrienoyl) glycerol

    (±)2-14,15-EG

    		 DNA/RNA Synthesis Metabolic Disease
    (±)2-(14,15-Epoxyeicosatrienoyl) glycerol ((±)2-14,15-EG) is a novel CYP450 metabolite of 2-Arachidonoyl glycerol (2-AG) in the kidney. (±)2-(14,15-Epoxyeicosatrienoyl) glycerol is a potent mitogen for renal epithelial cells, increasing DNA synthesis in LLCPKcl4 cells. (±)2-(14,15-Epoxyeicosatrienoyl) glycerol activates the metalloprotease ADAM17, which cleaves proTGF-α and releases TGF-α as a ligand that initiates the EGFR-ERK signalling pathway .
    (±)2-(14,15-Epoxyeicosatrienoyl) glycerol
  • HY-W770198
    2-Linoleoyl glycerol-d5

    2-Monolinolein-d5; 2-Monolinoleoylglycerol-d5

    		 Isotope-Labeled Compounds Cannabinoid Receptor Neurological Disease
    2-Linoleoyl glycerol-d5 (2-Monolinolein-d5; 2-Monolinoleoylglycerol-d5) is the deuterium labeled 2-Linoleoyl glycerol (HY-130311). 2-Linoleoyl glycerol (2-Monolinolein; 2-Monolinoleoylglycerol) is a monoacylglycerol that is an antagonist and partial agonist at the type 1 cannabinoid CB1 receptor. The potency of 2-Linoleoyl glycerol can be enhanced by JZL195 (HY-15250), an inhibitor of FAAH and MAGL, and inhibited by the CB1 antagonist AM251 (HY-15443) and Cannabidiol. As a CB1 antagonist, 2-Linoleoyl glycerol does not enhance, but only attenuates, the activity of the CB1/CB2 receptor ligands cannabinoids (AEA) and 2-arachidonoylglycerol (2-AG) [2].
    2-Linoleoyl glycerol-d5
  • HY-D2191
    Ag2S-COOH (1200 nm)

    		Fluorescent Dye Others
    Ag2S-COOH (1200 nm) is a fluorescent dyes.
    Ag2S-COOH (1200 nm)
  • HY-122256
    L-870812

    		HIV Integrase Infection
    L-870812 is a HIV-1 integration with integrase strand transfer inhibitor. L-870812 consistently blocks cell-free and cell-associated HIV-1 infection. L-870812 blocks subtype C and CRFO2_AG primary isolates. L-870812 can be used for the study of replication-deficient HIV-1 Ba-L (env) pseudovirus .
    L-870812
  • HY-117718R
    AG957 (Standard)

    Tyrphostin AG957 (Standard); NSC 654705 (Standard)

    		 Bcr-Abl Reference Standards Cancer
    AG957 (Standard) is the analytical standard of AG957. This product is intended for research and analytical applications. AG957 (Tyrphostin AG957;NSC 654705) is a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity [2]. AG957 is a bcr/abl kinase inhibitor with an IC50 of 2.9 μM for p210bcr/abl autokinase activity .
    AG957 (Standard)
  • HY-111297
    BMVC4

    		Biochemical Assay Reagents Cancer
    BMVC4 is a G-quadruplex (G4) stabilizer of the human telomeric sequence d[AG3(T2AG3)3]. Screening by circular dichroism (CD) spectroscopy revealed that BMVC4 is more suitable as the core molecule of G4 stabilizers than BMVC. The results showed that BMVC4-12C and BMVC4-8C3O are better candidates for G4 stabilizers and are worthy of further study. A simple and rapid screening method based on Cu2+-induced G4 unfolding can be used to find better G4 stabilizers for potential anticancer applications. CD results showed that the trivalent cations of 9-substituted BMVC derivatives are more suitable as G4 stabilizers than the divalent cations of BMVC. In addition, by monitoring the disappearance of the 291 nm CD band of human telomeres after Cu2+ addition, it was found that the core molecule of G4 stabilizer BMVC4 has better stability.
    BMVC4

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: